Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06518551 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary endpoint removed 3 → 2 primary endpoints
See other at-risk trials from Omar Nadeem, MD

Record History

  1. Primary endpoint(s) modified Eligibility criteria expanded, about 50 words · Secondary endpoints: 7 to 8 · Site details revised at 1 of 3 sites Show 3 more changesShow less
    • Eligibility criteria expanded, about 50 words
    • Secondary endpoints: 7 to 8
    • Site details revised at 1 of 3 sites
  2. Site details revised at 1 of 3 sitesv7
  3. Re-verified, no change to tracked fieldsv6
  4. Trial status: Not Yet Recruiting to Recruiting Site details revised at 3 of 3 sitesv5 Show 1 more changeShow less
    • Site details revised at 3 of 3 sites
  5. Start date: Oct 1, 2024 to Nov 1, 2024v4
Show 2 earlier versionsHide 2 earlier versions
  1. Start date: Sep 1, 2024 to Oct 1, 2024 Site contacts updated at 2 of 3 sites · Collaborators reorderedv3 Show 2 more changesShow less
    • Site contacts updated at 2 of 3 sites
    • Collaborators reordered
  2. Study title shortened, about 10 wordsv2 See this version in full on ClinicalTrials.gov ↗
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The aim of this research study is to evaluate the efficacy of Elotuzumab and Iberdomide therapy post-Idecabtagene Vicleucel in participants with relapsed and refractory multiple myeloma. The names of the study drugs involved in this study are: * Iberdomide (a type of cereblon E3 ligase modulator) * Elotuzumab (a type of monoclonal antibody) * Dexamethasone (a type of steroid)
Trial Details
NCT Number NCT06518551
Lead Sponsor Omar Nadeem, MD
Collaborators: Celgene, Bristol-Myers Squibb
Conditions Myeloma, Multiple Myeloma, Refractory Multiple Myeloma
Enrollment 49 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov